ESR1 and breast cancer: Studies have shown that 60%–70% of breast cancers are estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) hormone-dependent malignant tumors (Siegel RL et al., 2023; Trabert B et al., 2020).